Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
February 2014—Enzo Biochem published a study in Modern Pathology that shows a strong association between idiopathic pulmonary fibrosis (IPF) and the presence of the herpesvirus saimiri virus, a virus native to squirrel monkeys. The breakthrough discovery of the IPF’s origin is expected to result in a clinical diagnostic that could lead to screening and diagnosis, and perhaps result in potential treatment, for this fatal disease.
February 2014—Swift Biosciences announced the launch of the Accel-NGS PCR-free DNA Library Kit for Illumina next-generation sequencing systems. The kit is designed to bring low input requirement, PCR-free capability, and fast, easy workflow to the Illumina platform.
February 2014—Qiagen announced an agreement with Eli Lilly to develop and commercialize a molecular companion diagnostic paired with a novel Lilly oncology compound. This is the third co-development project by Qiagen and Lilly to create companion diagnostics.
February 2014—BioMérieux is moving forward with its comprehensive automation solution for reference or centralized molecular biology laboratories and has selected Life Technologies’ 7500 instruments as its preferred thermocyclers.
February 2014—Ventana Medical Systems’ HER2/neu (4B5) Rabbit Monoclonal Primary Antibody assay is a companion diagnostic for detecting HER2 protein expression in patients who, in countries where the drugs are approved, may be appropriate candidates for Perjeta (pertuzumab) and Kadcyla (ado-trastuzumab emtansine).
February 2014—Ventana Medical Systems received 510(k) clearance from the FDA for the Companion Algorithm ER (SP1) image-analysis algorithm used with the Ventana iScan Coreo scanner running Virtuoso software.
February 2014—Chembio Diagnostics, a provider of point-of-care diagnostic tests for infectious diseases, has filed a CLIA waiver application with the FDA for its DPP HIV 1/2 Assay.
February 2014—ViroStat has developed three new monoclonal antibodies to the nucleocapsid protein (N) of hantavirus. One of these recognizes all viruses tested (six) while the other two recognize four viral species. These new antibodies are useful tools to further the research of this viral genus.
February 2014—Enzo Life Sciences now offers a KIM-1 ELISA kit. Kidney injury marker 1 (KIM-1) is the most highly upregulated protein in the proximal tubule of the injured kidney and is detectable in the urine within six hours of injury. KIM-1 has been identified as an early diagnostic and prognostic marker of acute kidney injury resulting from illness, trauma, or nephrotoxicity, and with decreased kidney function and renal failure associated with chronic disorders such as diabetes and high blood pressure.
February 2014—Bioresearch equipment provider Labnet International has announced the launch of an addition to Labnet’s constant temperature equipment line with the release of the new AccuTherm Microtube Shaking Incubator.
